The latest price target for Cytokinetics (NASDAQ:CYTK) was reported by Cantor Fitzgerald on September 9, 2024. The analyst firm set a price target for $0.00 expecting CYTK to fall to within 12 months (a possible -100.00% downside). 51 analyst firms have reported ratings in the last year.

The latest analyst rating for Cytokinetics (NASDAQ:CYTK) was provided by Cantor Fitzgerald, and Cytokinetics reiterated their overweight rating.

There is no last upgrade for Cytokinetics

The last downgrade for Cytokinetics Inc happened on August 13, 2024 when Goldman Sachs changed their price target from $85 to $60 for Cytokinetics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytokinetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytokinetics was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.

While ratings are subjective and will change, the latest Cytokinetics (CYTK) rating was a reiterated with a price target of $0.00 to $0.00. The current price Cytokinetics (CYTK) is trading at is $56.50, which is out of the analyst’s predicted range.